Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo covers the nine-month period ended September 30, 2002, and the third quarter of 2002. The report details consolidated sales performance, product-specific growth, and recent regulatory and corporate developments.
Key Financial Metrics
Consolidated Sales (9 months 2002): 5,546 million euros, representing a 13.2% increase on a comparable basis and 15.3% on a reported basis.
Third Quarter Sales: 1,865 million euros, up 10.0% on a comparable basis.
Developed Sales (9 months 2002): 7,144 million euros, up 15.2% on a comparable basis. This metric includes sales from joint ventures with Bristol-Myers Squibb, Fujisawa, and Organon.
Top 15 Products: Generated 3,766 million euros (68% of total consolidated sales), up 20.4% on a comparable basis.
Share Buyback: As of September 30, 2002, the company held 8.8 million shares (1.2% of share capital) acquired under its buyback program.
Note: The filing does not provide specific figures for net profit, operating margins, cash flow, debt levels, or liquidity ratios.
Material Changes vs. Prior Period
- Geographic Performance: Sales grew in all regions: Europe (+12.6%), United States (+16.4%), and Rest of the World (+11.4%).
- Product Growth:
- Plavix(R)/Iscover(R): Developed sales up 32.4% (9 months); Consolidated sales up 42.9%.
- Stilnox(R)/Ambien(R): Developed sales up 32.0% (9 months); Consolidated sales up 31.9%.
- Aprovel(R)/Avapro(R): Developed sales up 22.2% (9 months); Consolidated sales up 34.7%.
- Eloxatin(R): Consolidated sales surged 61.1% following its U.S. launch in August 2002.
- Declining Products: Corotrope(R)/Primacor(R) sales fell 32.2% due to generic competition; Ticlid(R) sales fell 31.0%.
- Structural Changes: Favorable impact of 3.9 points from consolidation changes (Lorex, Fujisawa, Ela Medical).
- Currency Impact: Adverse effect of 1.8 points on comparable sales growth for the nine-month period.
Outlook, Risks, and Recent Events
Guidance: Management projects net profit attributable to the Group (before exceptional items and goodwill amortization) to grow by over 25%, barring major adverse events.
Recent Events:
- U.S. launches of Eloxatin(R), Elitek(R), and Eligard(R).
- U.S. approval for Avapro(R) in diabetic nephropathy treatment.
- European approval for Plavix(R) in acute coronary syndrome.
- New patent registration for Plavix(R) crystalline form 2.
Risks and Contingencies:
- Success of R&D programs and expansion in the U.S. market.
- Protection of intellectual property rights.
- Healthcare cost reimbursement and pricing reforms, particularly in the U.S. and France.
- Inventory management actions by partners (e.g., Bristol-Myers Squibb reducing Avapro(R) inventories).
Investor Verification Checklist
- Verify the specific definition of "Developed Sales" versus "Consolidated Sales" to understand the impact of joint venture accounting.
- Confirm the sustainability of Plavix(R) growth given the noted slowdown in Q3 due to reduced sales to Bristol-Myers Squibb.
- Monitor the impact of generic competition on Corotrope(R)/Primacor(R) and Ticlid(R) on future margins.
- Assess the timeline for the full financial impact of the new U.S. product launches (Eloxatin, Elitek, Eligard).
- Review upcoming full-year financial statements for actual net profit figures to validate the >25% growth guidance.